Current Allergy and Asthma Reports

, Volume 11, Issue 1, pp 7–11

Interleukin-33 in Asthma: How Big of a Role Does It Play?


DOI: 10.1007/s11882-010-0153-8

Cite this article as:
Borish, L. & Steinke, J.W. Curr Allergy Asthma Rep (2011) 11: 7. doi:10.1007/s11882-010-0153-8


In complex disorders such as asthma and allergic disease, the goal for developing disease-modifying biotherapeutics is to find a target that is a central instigator of immunologic activity. Interleukin (IL)-33 seems to be such a molecule, as it is one of the earliest-released signaling molecules following epithelial damage and can orchestrate the recruitment and activation of the cells responsible for disease. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils, and basophils, ultimately leading to increased expression of cytokines and chemokines that define the disease. As such, IL-33 is an attractive candidate for therapeutic intervention with the goal of ameliorating disease. This review focuses on the role of IL-33 in promoting and maintaining the asthma phenotype.


Asthma Interleukin-33 ST2 Interleukin-1 family 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Asthma and Allergic Disease Center, Box 801355University of Virginia Health SystemsCharlottesvilleUSA

Personalised recommendations